Uroplasty Inc

Uroplasty — Investor Presentation (February 2008)

34 slides from Uroplasty's investor presentation, Feb 20, 2008

  1. Slide 1: Uroplasty, Inc

    Uroplasty, Inc Presented by David Kaysen, President & CEO Medi Jiwani, Vice President, CFO & Treasurer

  2. Slide 2: Forward Looking Statement

    This presentation includes forward-looking statements, including financial projections, relating to our business plan and growth strategies. For many reasons we may not achieve our financial objectives or successfully grow our business. Our reports filed with the U.S. Securities and Exchange Commiss

  3. Slide 3: Overactive Bladder (OAB) Market

    ~33 million persons in the United States ~16.5% of our population grapple with the problem of overactive bladder (OAB) ~30% of these persons are bothered enough to seek treatment Overactive Bladder (OAB) Market

  4. Slide 4: Overactive Bladder (OAB) Drugs

    Roughly 55% of these patients (4 million) cannot tolerate OAB drug therapy "A lack of efficacy, along with the persistent issue of side effects, contributes to a significant dropout rate for [OAB] pharmacotherapy." -- Dr. Victor Nitti, New York University Medical Center, "Interstim: A Decade of Sacr

  5. Slide 5: Non-Drug OAB Options

    Behavioral therapy Non-Drug OAB Options Dietary modification Minimally-Invasive - Urgent PC(r) Neuromodulation Surgery - Interstim(r) Therapy Reconstructive Surgery - bladder augmentation, urinary diversion

  6. Slide 6: Uroplasty is...

    Uroplasty is... Revolutionizing how urologists and urogynecologists are treating non-invasively a debilitating problem. Providing unique products for the treatment of urinary voiding dysfunctions. Commercializing its Urgent(r) PC system, which the Company believes is the only non-surgical neurostimu

  7. Slide 7: Urgent PC

    Urgent PC - Neurostimulation Consists of handheld stimulator with lead set 30-minute office based treatment, can be nurse administered Minimally invasive Provides percutaneous tibial nerve stimulation (PTNS) for the treatment of urinary urgency, urinary frequency and urge incontinence. Have shown PT

  8. Slide 8: Company Profile

    AMEX Listing: UPI Closing Price(1): $4.08 Market Capitalization(1): $61 million Revenues: $12.3 million (last 12 months ended 12/31/07) $7.0 million (last 12 months ended 12/31/06) $14.9 million (L3M run rate) Operations: Headquartered in Minneapolis, MN Subsidiaries: Netherlands and United Kingdom

  9. Slide 9: Market Factors

    Large and growing market opportunity The U.S. neurostimulation device market is expected to grow from approximately $628 million in 2006 to approximately $2 billion in 2012 Overactive bladder (OAB) is a prevalent and challenging urologic problem affecting an estimated 33 million Americans Female Str

  10. Slide 10: Company Highlights

    Experienced management team - track record of demonstrated success U.S. sales strategy Single office/outpatient call point for both OAB and SUI products Recently launched direct sales force in U.S. Favorable reimbursement and very compelling economics for doctors Positioned for profitability and con

  11. Slide 11: Urgent PC is Uroplasty's Growth Driver

    Urgent(r) PC is Uroplasty's Growth Driver $6.0 $6.5- $7.0

  12. Slide 12: Macroplastique is Uroplasty's Legacy Product

    Biocompatible urethral bulking agent Unique delivery system ensures precise implantation 30-min office based/outpatient procedure Minimally invasive treatment Macroplastique is an injectable soft-tissue bulking agent used to treat adult female stress urinary incontinence (SUI) primarily due to intri

  13. Slide 13: International Market Coverage

    International Market Coverage International Market Coverage United Kingdom Employed Sales Representative (5) Independent Sales Representative (1) International - Distributors Presence in 43 countries worldwide throughout: Europe North America South America Central America Africa Middle East Asia Aus

  14. Slide 14: Urinary Disorders: $3.1 Billion U.S. Market

    $3.1 Billion U.S. Market Our primary demographic is women between 40 and 60 years old 3 Million patients Stress Urge Incontinence 33 Million patients Urgency Frequency Urge Incontinence 14 Million patients Involuntary leaking during increased intra-abdominal pressure (SUI) Overactive Bladder (OAB) M

  15. Slide 15: Uroplasty Solution: OAB Treatment Continuum of Care

    OAB Treatment Options - Continuum of Care Treatment Company and Product Names Position Drug Therapy Pharmacia - Detrol(r) ALZA - Ditropan(r) Watson Pharma - Oxytrol(r) Negative side effects Surgery Medtronic - InterStim(r) Other Reconstructive Surgery Expensive procedure and invasive surgery Neuro S

  16. Slide 16: Urgent PC U.S. Sales Strategy

    Urgent PC U.S. Sales Strategy Direct U.S. Sales force is currently comprised of 18 direct representatives supplemented by 11 independent representatives Target Market: ^8,500 Total U.S. Urologists/Urogynecologists Market Penetration Today Target Market Penetration 3 Years From Today ^2 to 3% ^20%

  17. Slide 17: U.S. Market Coverage

    U.S. Market Coverage Hawaii Employed Sales Representative (18) Independent Sales Representative (11) Employed Representative to be added (2)

  18. Slide 18: Urgent PC Marketing Strategy

    Urgent PC Marketing Strategy We intend to market the Urgent PC brand with the following strategies... Clinical trials to educate the doctor community Patient education and literature for doctors' offices Physician & nursing society meetings Investor relations Website redesign Physician locator UPC f

  19. Slide 19: Physician Economics with Urgent PC

    Physician Economics with Urgent PC Economics are very compelling for physicians... Reusable Stimulator $1,500 Disposable Lead Set $780 (12 each per treatment series) Reimbursement $2,220 - $3,900 (per treatment series)

  20. Slide 20: Management Team

    Name Title Previous Experience Dave Kaysen President & CEO Diametrics, Rehabilicare Medi Jiwani CFO Gedney, Telex Communications, Tennant Susan Holman COO Bioplasty, Bio-Vascular Larry Heinemann VP Sales C.R. Bard Nancy Kolb VP Marketing Inlet Medical, Gyrus Medical Marc Herregraven VP Manufacturing

  21. Slide 21: Financial Presentation

    FINANCIAL PRESENTATION

  22. Slide 22: Revenue Growth

    Revenue Growth $6.0 $6.5 - $7.0

  23. Slide 23: Urgent PC is the Growth Driver

    Urgent PC is the Growth Driver

  24. Slide 24: Sales by Geographic Areas

    Sales by Geographic Areas U.S. accounts for a greater portion of the increasing sales

  25. Slide 25: Income Statement (non-GAAP)

    Income Statement (non-GAAP) Projected operating profit (excluding non-cash & unusual charges) breakeven at ~ $16 million sales

  26. Slide 26: Income Statement (non-GAAP)

    Income Statement (non-GAAP) Projected operating profit (excluding non-cash & unusual charges) breakeven at ~ $16 million sales

  27. Slide 27: Financial Model (non-GAAP)

    Financial Model (non-GAAP)

  28. Slide 28: Balance Sheet

    Balance Sheet (dollars in thousands) 12/312007 Cash, cash equivalents & ST Investments $10,307 Other Working Capital 401 Total Assets 19,261 Long-Term Debt 406 Shareholders’ Equity 15,842

  29. Slide 29: Capital Structure

    Capital Structure 1239/2007 (inmittions) 14.9 Common Shares Outstanding Options (weighted average exercise price =$4.01) Outstanding Warrants (weighted average exercise price = $281) Total

  30. Slide 30: Reconciliation of non-GAAP financial measures to GAAP

    Reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures

  31. Slide 31: Reconciliation of non-GAAP financial measures to GAAP

    Reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures

  32. Slide 32: Reconciliation of non-GAAP financial measures to GAAP

    Reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures

  33. Slide 33: Reconciliation of non-GAAP financial measures to GAAP

    Reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures

  34. Slide 34: Questions

    Questions €3 Uropllasiy SsoldionslfomVolding Dysfunctions

Uroplasty — Investor Presentation (February 2008) on 6ix